Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 3/20 | 0.33 |
| ▸ | FLT4 | P35916 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | FBP1 | P09467 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6847201 | 0.87 | CCR4 (0.43) | CCR4CCKBRKMT2AF2FLT1 | |
| SCHEMBL7570277 | 0.84 | OPRD1 (0.38) | — | |
| SCHEMBL7562585 | 0.82 | CCR4 (0.48) | CCR4CCKBRKMT2AFLT1FLT4 | |
| SCHEMBL7567612 | 0.81 | CCR4 (0.42) | CCR4CCKBRKMT2AFLT1FLT4 | |
| SCHEMBL6807241 | 0.79 | — | — | |
| SCHEMBL6807252 | 0.79 | CCR4 (0.40) | CCR4CCKBRKMT2AFBP1 | |
| SCHEMBL6807253 | 0.77 | CCR4 (0.40) | CCR4CCKBRKMT2A | |
| SCHEMBL6802953 | 0.76 | CCR4 (0.38) | CCR4CCKBR | |
| SCHEMBL1548108 | 0.75 | CCR4 (0.41) | CCR4CCKBRKMT2ATDP1 | |
| SCHEMBL6802957 | 0.74 | CCR4 (0.38) | CCR4CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010142-A1 | Novel process | NOVO NORDISK A/S (DK) | 2004-01-15 | — | — | US | disclosed |
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010142-A1 | Novel process | UGT1A1, CYP4X1, CYP4B1 | CCR4 2292/4885CCKBR 977/4885KMT2A 4646/4885 |
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | CCR4 3947/4885CCKBR 1602/4885KMT2A 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.